The process is rigorous and involves multiple levels of review within and outside the newsroom.

WSJ: 'What About the Journal?' A Report from the Special Committee

The multiple layers of review at the Big Pharma company can be a waste of its own time.

FORBES: Can the Big Pharma Elephant Learn to Dance?

Shares in Biogen Idec dipped 2.7% not only because the Food and Drug Administration said it would take an extra three months to review its key multiple sclerosis drug, BG-12, but because an Abbott Laboratories kidney cancer medicine that in some ways works similarly to BG-12 failed.

FORBES: Biogen Says Its FDA Delay Unrelated To Abbott's Failed Medicine